Palliativmedizin bei neurologischen Erkrankungen

Abstract

From the start of modern hospice and palliative care, patients with non-tumor conditions were also cared for. Among those, neurological disorders constitute the largest group of patients. In Germany, only recently, specialized palliative home care has become mandatory part of the national ehealth care system. The now published frameworks for that only speak of needs and not disorders, therefore paving the way for more neurological patients within palliative care structures in the future. This article provides an up-to-date overview on palliative care for patients with brain tumors, amyotrophic lateral sclerosis, Parkinson syndromes and multiple sclerosis.

Literatur

• 1 Mintz A, Perry J, Spithoff K. et al . Management of single brain metastasis: a practice guideline.  Curr Oncol. 2007;  14 131-143
• 2 Prados M D, Levin V. Biology and Treatment of Malignant Glioma.  Seminars in Oncology. 2000;  27 (Suppl. 6) 1-10
• 3 Chen G, Huynh M, Chen A. et al . Chemotherapy for brain metastases in small-cell lung cancer.  Clin Lung Cancer. 2008;  9 35-38
• 4 Behar R, Abu Rkih R. Does the patient with a primary brain tumour need hospice? Abstracts of the 7th. Congress of EAPC.  Eur J Pall Care. 2001;  12 120
• 5 Bausewein C, Borasio G D, Voltz R. Primary Brain Tumours. In: Doyle D, Hanks G, Cherny N, Calman K, eds Oxford Textbook of Palliative Medicine. 3rd. ed. Oxford; Oxford University Press 2004: 727-730
• 6 Davies E, Higginson I J. Communication, information and support for adults with malignant cerebral glioma: a systematic literature review.  Support Care Cancer. 2003;  11 21-29
• 7 Burchardi N, Rauprich O, Hecht M. et al . Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients.  J Neurol Sci. 2005;  237 67-74
• 8 Adelbratt S, Strang P. Death anxiety in brain tumour patients and their spouses.  Palliative Medicine. 2000;  14 499-507
• 9 Forsyth P A, Posner J B. Headaches in patients with brain tumors: a study of 111 patients.  Neurology. 1993;  43 1678-1683
• 10 Vecht C J, Hovestadt A, Verbiest H B. et al . Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumours: a randomized study of doses of 4, 8 and 16 mg per day.  Neurology. 1994;  44 675-680
• 11 Brogna C, Gil Robles S, Duffau H. Brain tumors and epilepsy.  Expert Rev Neurother. 2008;  8 941-955
• 12 Kurthen M, Bauer J, Janzen C. et al . Status epilepticus im Erwachsenenalter. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 20-27
• 13 van Breemen M S, Wilms E B, Vecht C J. Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management.  Lancet Neurol. 2007;  6 421-430
• 14 Elger C E, Bauer J, Janzen C. et al . Epilepsie im Erwachsenenalter. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 8-17
• 15 Lorenzl S, Mayer S, Noachtar S. et al . Nonconvulsive status epilepticus in terminally ill patients – a diagnostic and therapeutic challenge.  J Pain Symptom Manage. 2008;  36 200-205
• 16 Bausewein C, Roller S, Voltz R. Delirantes Syndrom. Leitfaden Palliativmedizin Palliative Care. 3. Aufl. München; Urban & Fischer Elesevier 2007: 326-331
• 17 Bausewein C, Hau P, Voltz R. et al . How do patients with brain tumours die?.  Palliat Med. 2003;  17 558-559
• 18 Oliver D, Borasio G D, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis – From Diagnosis to Bereavement. 2nd. ed. Oxford; Oxford University Press 2006
• 19 Borasio G D, Sloan R, Pongratz D E. Breaking the news in amyotrophic lateral sclerosis.  J Neurol Sci. 1998;  160 (Suppl. 1) S127-S133
• 20 Borasio G D, Husemeyer I M. Ernährung bei Schluckstörungen. 6. Aufl. Stuttgart; Kohlhammer 2004
• 21 Neudert C, Oliver D, Wasner M. et al . The course of the terminal phase in patients with amyotrophic lateral sclerosis.  J Neurol. 2001;  248 612-616
• 22 Miller R G, Rosenberg J A, Gelinas D F. et al . Practice Parameter: The care of the patient with amyotrophic lateral sclerosis.  Neurology. 1999;  52 1311-1323
• 23 Borasio G D, Voltz R. Discontinuation of life support in patients with amyotrophic lateral sclerosis.  J Neurol. 1998;  245 717-722
• 24 Mazzocato C, Buclin T, Rapin C H. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial.  Ann Oncol. 1999;  10 1511-1514
• 25 Ganzini L, Johnston W S, McFarland B H. et al . Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide.  N Engl J Med. 1998;  339 967-973
• 26 Giess R, Naumann M, Werner E. et al . Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis.  J Neurol Neurosurg Psychiatry. 2000;  69 121-123
• 27 Sykes N, Thorns A. The use of opioids and sedatives at the end of life.  Lancet Oncology. 2003;  4 312-318
• 28 Mark M H. Lumping and splitting the Parkinson plus syndromes: Dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortico-basal ganglionic degeneration.  Neurol Clin. 2001;  19 607-627
• 29 Bunting-Perry L K. Palliative care in Parkinson's disease: implications for neuroscience nursing.  J Neurosci Nurs. 2006;  38 106-113
• 30 Daniele A, Moro E, Bentivoglio A R. Zolpidem in progressive supranuclear palsy.  N Engl J Med. 1999;  341 543-544
• 31 Nath U, Ben-Shlomo Y, Thomson R G. et al . Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study.  Neurology. 2003;  60 910-916
• 32 Papapetropoulos S, Singer C, McCorquodale D. et al . Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP).  Parkinsonism Relat Disord. 2005;  11 459-463
• 33 Flachenecker P. Epidemiology of neuroimmunological diseases.  J Neurol. 2008;  255 308
• 34 Matthews B. Symptoms and signs of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, Mc Donald I, Matthews B, Wekerle H, eds McAlpine's Multiple Sclerosis. 3rd. ed. Oxford; Elsevier 1998: 145-191
• 35 Multiple Sclerosis Therapy Consensus Group (MSTCG) .Basic and escalating immunomodulatory treatments in multiple sclerosis – Current therapeutic recommendations. J Neurol 2008 [im Druck]
• 36 Higginson I J, Hart S, Silber E. et al . Symptom prevalence and severity in people severely affected by multiple sclerosis.  J Palliat Care. 2006;  22 158-165
• 37 Edmonds P, Vivat B, Burman R. et al . Loss and change: experiences of people severely affected by multiple scerosis.  Palliative Medicine. 2007;  21 101-107
• 38 Edmonds P, Vivat B, Burman R. et al . „Fighting for everything”: service experiences of people severely affected by multiple sclerosis.  Multiple Sclerosis. 2007;  13 660-667
• 39 Kümpfel T, Hoffmann L A, Pöllmann W. et al . Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists.  Palliate Med. 2007;  21 109-114
• 40 Stenager E N, Stenager E, Koch-Henrikson N. et al . Suicide and multiple sclerosis: an epidemiological investigation.  J Neurol Neurosurg Psychiatry. 1992;  55 542-545
• 41 Feinstein A. An examination of suicidal intent in patients with multiple sclerosis.  Neurology. 2002;  59 674-678
• 42 van der Wal G, Onwuteaka-Philipsen B D. Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years.  BMJ. 1996;  312 612-613
• 43 Henze T, Rieckmann P, Toyka K V. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society . Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.  Eur Neurol. 2006;  56 78-105
• 44 Rieckmann P, Toyka K, Fasshauer E. Diagnostik und Therapie der Multiplen Sklerose. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 298-316
• 45 Noth J, Dietz V, Ochs G. Spastik. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 596-603
• 46 Bever Jr C T, Young D, Anderson P A. et al . The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.  Neurology. 1994;  44 (6) 1054-1059
• 47 Panitch H S, Thisted R A, Smith R A. et al . Randomized, controlled trial of dextromethorphan / quinidine for pseudobulbar affect in multiple sclerosis.  Ann Neurol. 2006;  59 780-787